Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Extension Study of T-1101 (Tosylate) Administered Orally to Patients With Advanced Refractory Solid Tumors

NCT03349073 is registered in ClinicalTrials.gov with Taivex Therapeutics Corporation as lead sponsor.

NCT NCT03349073
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03349073 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Extension Study of T-1101 (Tosylate) Administered Orally to Patients With Advanced Refractory Solid Tumors
Lead sponsor
Taivex Therapeutics Corporation
Phase
Phase 1
Overall status
Completed
Start date
September 14, 2017
Completion date
June 24, 2019
Enrollment
3 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

advanced refractory solid tumors